Lonafarnib
Back to searchMolecule Structure
Scientific Name
Lonafarnib
Description of the Drug
Lonafarnib is a potent farnesyl transferase inhibitor used to reduce mortality associated with Hutchinson-Gilford progeria syndrome (HGPS) and other progeroid laminopathies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06448
http://www.drugbank.ca/drugs/DB06448
Brand Name(s)
Zokinvy
Company Owner(s)
Eiger Biopharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Protein farnesyltransferase | PROTEIN COMPLEX | INHIBITOR | CHEMBL2094108 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19032 | |
| PharmGKB | PA166129466 | |
| Human Metabolome Database | HMDB0304871 | |
| DrugBank | DB06448 | |
| PubChem: Thomson Pharma | 14863416 | 14839125 |
| PubChem | 148195 | |
| NMRShiftDB | 60053078 | |
| LINCS | LSM-45716 | |
| Nikkaji | J1.013.643A | |
| PDBe | 336 | |
| BindingDB | 14459 | |
| EPA CompTox Dashboard | DTXSID90172927 | |
| DrugCentral | 5414 | |
| Brenda | 25474 | 13749 |
| ChemicalBook | CB31011743 | |
| Guide to Pharmacology | 8024 | |
| PubChem: Drugs of the Future | 12015147 | |
| ChEBI | 47097 | |
| ZINC | ZINC000003950115 |
